血清sICAM-1、VEGF、sFas水平在急性白血病中的变化及临床价值  

Changes and clinical value of serum sICAM-1,VEGF and sFas levels in acute leukemia

作　　者：何昊 郑克春 周友根 漆星 HE Hao;ZHENG Kechun;ZHOU Yougen;QI Xing(Department of Clinical Laboratory,Anyue County People′s Hospital,Ziyang,Sichuan 642350,China;Department of Clinical Laboratory,Ziyang City First People′s Hospital,Ziyang,Sichuan 641300,China)

机构地区：[1]安岳县人民医院检验科,四川资阳642350 [2]资阳市第一人民医院检验科,四川资阳641300

出　　处：《国际检验医学杂志》2024年第12期1487-1490,共4页International Journal of Laboratory Medicine

摘　　要：目的探讨血清可溶性细胞间黏附分子-1(sICAM-1)、血管内皮生长因子(VEGF)、可溶性跨膜蛋白(sFas)在急性白血病中的变化及临床意义。方法选取2020年5月至2022年5月安岳县人民医院收治的急性白血病患者89例为观察组,另选同时段该院的体检健康者65例为对照组。所有患者入院后给予化疗,对其实施1年电话、门诊随访。比较两组患者血清sICAM-1、VEGF、sFas水平差异,比较不同疗效、不同预后急性白血病患者血清sICAM-1、VEGF、sFas水平差异。绘制受试者工作特征(ROC)曲线,评估相关指标对急性白血病疗效、预后的预测价值。结果与对照组比较,观察组血清sICAM-1、VEGF、sFas水平升高(P<0.05)。与非完全缓解(CR)患者比较,CR患者血清VEGF水平升高(P<0.05)。与预后良好患者比较,预后不良患者血清sICAM-1、VEGF、sFas水平升高(P<0.05)。ROC曲线分析结果显示,VEGF评估急性白血病疗效的曲线下面积(AUC)为0.778,sICAM-1、VEGF、sFas单独与联合评估急性白血病预后的AUC分别为0.793、0.729、0.666、0.889。结论血清sICAM-1、VEGF、sFas在急性白血病患者中水平升高,sICAM-1、VEGF、sFas联合评估急性白血病疗效、预后均有一定临床参考价值。Objective To investigate the changes and clinical significance of serum soluble intercellular adhesion molecule-1(sICAM-1),vascular endothelial growth factor(VEGF)and soluble across a membrane protein(sFas)in acute leukemia.Methods A total of patients with acute leukemia admitted to the People′s Hospital of Anyue County from May 2020 to May 2022 were selected as the observation group,and 65 healthy people who underwent physical examination in the hospital during the same period were selected as the control group.All patients were treated with chemotherapy after admission,and followed up by telephone and outpatient for 1 year.The levels of serum sICAM-1,VEGF and sFas were compared between the two groups,and the levels of serum sICAM-1,VEGF and sFas were compared between the patients with different efficacy and different prognosis.The receiver operating characteristic(ROC)curve was established to evaluate the predictive value of related indicators for the efficacy and prognosis of acute leukemia.Results Compared with control group,the levels of serum sICAM 1,VEGF,sFas in the observation group were increased(P<0.05).Compared with the non-complete remission(CR)patients,the serum VEGF level in CR patients was significantly increased(P<0.05).Compared with the good prognosis patients,the levels of serum sICAM-1,VEGF and sFas in the poor prognosis patients were increased(P<0.05).ROC curve analysis showed that the area under the curve(AUC)of VEGF in evaluating the efficacy of acute leukemia was 0.778.The AUC for evaluating the prognosis of acute leukemia with sICAM-1,VEGF,and sFas alone and in combination were 0.793,0.729,0.666,and 0.889,respectively.Conclusion The levels of serum sICAM-1,VEGF and sFas are increased in patients with acute leukemia.The combination of sICAM-1,VEGF and sFas has certain clinical reference value in evaluating the efficacy and prognosis of acute leukemia.

关 键 词：可溶性细胞间黏附分子-1 血管内皮生长因子 可溶性跨膜蛋白 急性白血病 

分 类 号：R733.7[医药卫生—肿瘤]